Stanford researchers have engineered hematopoietic stem cells to provide long-term secretion of chosen therapeutic antibodies, eliminating the need of repeated dosing for delivery.
(a)Antibodies Against Rat Hormone-Sensitive Lipase (399-608) Fusion Protein and•(b)Vector for Rat Hormone-Sensitive Lipase (nt 1810-2438) Fusion Protein
Researchers at Stanford have developed a nanoparticle-based platform to enhance activation of self-specific CD8+ T cells in the tumor microenvironment to fight cancer while minimizing toxic side effects.
Stanford researchers have developed a high-affinity IL-11 decoy cytokine for super-agonism and antagonism of the IL-11 receptor, enabling the treatment of a wide variety of diseases from inflammatory disease to cancer as well as research into IL-11 signaling pathways.
This invention consists of mouse L1/2 pre B cells and human Jurkat cells transfected with serpentine receptors. These cell lines have been shown to be induced by specific ligands to activate lymphoid cell integrins and hence cell adhesion.
A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Glaucoma results from the loss of retinal ganglion cells (RGCs), the primary output neurons of the retina that connect to brain areas responsible for vision. Current treatments focus on lowering intraocular pressure but do not prevent blindness in about 25% of patients.
Heart failure has a prognosis worse than most cancers and affects over five million people in the United States alone. Although some medications for heart failure exist, many patients develop side effects or do not respond favorably to existing medications.
Researchers at Stanford and WashU developed cannabinoid receptor agonists with distribution mainly to peripheral tissues. Cannabinoid agonists are relevant for treatment of many indications, but current clinical use is limited by a variety of side effects.
Researchers at Stanford and the University of Helsinki discovered that a human secretoglobin protein found in sweat gland cells acts as a novel host defense mechanism against Lyme disease.
Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents.